Category: ACN Newswire

香港，2025年8月15日 - (亚太商讯 via SeaPRwire.com) - 云顶新耀今日宣布，旗下创新药艾曲莫德（VELSIPITY(R)，etrasimod）被纳入《2025 ACG 临床指南：成人溃疡性结肠炎》（下称"新版指南"），并获得强烈推荐用于中重度活动性溃疡性溃疡性结肠炎（UC）患者的诱导缓解及维持缓解治疗（中等质量证据）。新版指南同时建议，对于已通过鞘氨醇-1-磷酸（S1P）受体调节剂实现诱导缓解的患者，继续使用艾曲莫德以维持缓解（强烈推荐，中等质量证据）。这一重要进展不仅体现了国际权威医学指南对艾曲莫德临床价值的高度认可，也进一步彰显了其在满足UC患者未被满足的治疗需求方面的潜力，为全球UC患者提供新的治疗选择。此次新版指南由美国胃肠病学会（American College of Gastroenterology，ACG）制定，基于近五年最新循证医学证据，系统总结了UC治疗及并发症预防的新方法与新进展，为临床医生提供规范、科学的管理参考，以更好地应对不同程度的UC患者治疗需求。新版指南指出，艾曲莫德作为新一代高选择性S1P受体调节剂，通过将活化的淋巴细胞滞留于淋巴结中，减少其在肠道中的浸润，从而降低局部炎症反应，并伴随外周循环淋巴细胞计数下降。艾曲莫德ELEVATE UC III 期注册研究（ELEVATE UC 52和ELEVATE UC 12）这两项随机、双盲、安慰剂对照研究均达到了所有主要和关键次要终点，分别在第12周和第52周显著改善临床缓解率，并实现持久的内镜下深度黏膜愈合。值得注意的是，研究中100%的临床缓解均为无激素缓解，安全性良好，与既往研究结果一致。指南也特意强调了与其他现有治疗不同的是，艾曲莫德 ELEVATE UC III 期注册研究中纳入了溃疡性直肠炎，且证实了在此类人群中显著提升了临床缓解率（治疗12周时，43.2% vs 13.6%, p＜0.001）。此前，艾曲莫德还被纳入2024年美国胃肠病学协会（AGA）临床实践指南, 推荐作为溃疡性结肠炎的一线治疗。艾曲莫德亚太临床试验牵头研究者、世界胃肠病学会司库、亚太消化病学会副主席、中华医学会第十届消化病学分会副主任委员、中国人民解放军第四军医大学附属西京医院吴开春教授表示："新版指南进一步明确，'实现内镜黏膜愈合以达成持续无激素缓解和避免住院手术'是中重度溃疡性结肠炎治疗的核心目标，这不仅关系到疾病的长期安全管理，也与改善患者生活质量息息相关。此次指南中，艾曲莫德被强烈推荐用于中重度活动性溃疡性结肠炎的诱导和维持治疗，标志着其临床价值获得了国际权威学术机构的高度认可，也为临床实践提供了全新的治疗选择。"云顶新耀首席执行官罗永庆表示："艾曲莫德此次获新版指南强烈推荐用于中重度活动性溃疡性结肠炎的诱导和维持治疗，充分体现了其卓越的临床疗效和良好安全性，进一步确立了其作为一线治疗新选择的重要地位。新版指南明确将实现内镜黏膜愈合作为治疗中重度活动性溃疡性结肠炎的核心目标，印证了黏膜愈合为国内外指南一致认定的重要终点，可显著降低疾病复发、住院、结直肠切除及结直肠癌风险。值得一提的是，指南特别强调了艾曲莫德在溃疡性直肠炎患者中同样可显著提升临床缓解率。在亚洲，溃疡性结肠炎患者人数持续上升，以中国为例，2024年中国的溃疡性结肠炎患者数量约为80万人，预计到2030年将达100万人，现有临床治疗选择有限，迫切需要兼顾疗效、安全性与便利性的创新方案。我们将加速艾曲莫德的商业化进程，助力更多患者长期维持安全有效的疾病缓解，并提升生活质量。"作为云顶新耀在自身免疫疾病领域布局的核心创新产品，艾曲莫德（维适平(R)）的新药上市申请已于2024年12月获中国国家药品监督管理局正式受理，预计今年年底或明年年初获批。艾曲莫德已在新加坡、中国澳门和中国香港获批，其新药上市许可申请也已在韩国和中国台湾地区获正式受理。艾曲莫德已被纳入粤港澳大湾区内地9市临床急需进口港澳药品医疗器械目录（2024年），在大湾区先行使用，成为云顶新耀第三款商业化新药。云顶新耀已于2025年3月启动艾曲莫德在嘉善工厂的本地化生产建设项目，支持其在大中华区及其他亚洲市场的供应及商业化落地。 Copyright 2025 亚太商讯 via SeaPRwire.com.

业绩亮点：- 收入达83.6百万美元，同比增长5.9%。- 销量达919,000件，其中779,000件为自有产品，同比增长8.6%。- 公司拥有人应占利润同比上升5.1%至19.8百万美元。- 核心经营利润达15.1百万美元，同比增长11.4%。- 为庆祝集团成立25周年，董事会宣派特别股息每股15港仙。- 财务状况稳健，截至2025年6月30日，现金及银行结余达237.1百万美元，支持潜在收购及新生产设施建设。- 优质产品获全球广泛认可，带动亚太地区市场收入按年增长14.0%，欧洲、中东及非洲市场增长17.0%，及美国市场增长20.0%。- 于上半年收购一家台湾经销商，并计划下半年于比利时及荷兰设立直销团队，进一步加强在亚太地区及欧洲、中东及非洲市场的影响力。- 集团善用全球商业化专长及庞大销售网络，与医疗器械同业建立战略合作，藉此丰富产品组合，并透过交叉销售创造额外收入。香港，2025年8月15日 - (亚太商讯 via SeaPRwire.com) - 专营经皮冠状动脉介入治疗（PCI）及经皮腔内血管成形术（PTA）手术介入器械的全球医疗器械制造公司业聚医疗集团控股有限公司（"业聚医疗"或"集团"；股份代号：6929）今天宣布截至2025年6月30日止六个月("报告期")的中期业绩。尽管宏观经济环境未见明朗，集团的收入及纯利仍双双录得增长。美国市场增长强劲，加上亚太地区及欧洲、中东与非洲地区新兴市场的持续贡献，推动集团收入达到83.6百万美元，较去年同期上升5.9%。核心经营利润（自本公司拥有人应占利润撇除以股份为基础的薪酬开支、与税务亏损相关的递延税项资产的税务抵免净额及融资收入╱成本）为15.1百万美元，同比增长11.4%。公司拥有人应占利润同比上升5.1%至19.8百万美元。每股基本盈利为2.40美仙（2024年上半年：2.28美仙）。截至2025年6月30日，集团财务状况保持稳健，现金及银行结余达237.1百万美元。鉴于集团的财务状况稳健，以及为庆祝成立25周年，董事会议决宣派特别现金股息每股普通股15港仙，彰显集团致力为股东创造价值。连同截至2024年12月31日止年度之末期股息每股10港仙（已于2025年6月16日派付），股东于2025年合共获派股息每股25港仙。业聚医疗董事长、执行董事兼首席执行官钱永勋先生表示："过去25年，我们持续投资于创新及全球商业化能力，除了为业聚医疗建立了声誉，也助我们在不同的经济周期中破浪前行。尽管2025年上半年面临宏观经济及地缘政治的双重挑战，我们的全球布局仍展现韧性。美国市场增长印证了市场对我们的优质产品需求殷切，而我们亦透过庞大的销售网络，成功把握了亚太地区及欧洲、非洲及中东地区的增长机遇。我们将继续透过直销市场覆盖、卓越的销售支援、对创新的投入，以及全面的PCI和PTA产品组合提升品牌价值，从而强化竞争优势，为医生及患者提供更安全有效治疗方案的同时，也为股东创造长远回报。"全球销售网络及合作伙伴关系推动收入增长业聚医疗已建立覆盖逾70个国家及地区的销售网络，在13个地区设立直销团队并建立全球经销商网络，成为把握各地机遇、回应当地需求的重要一环。期内，受惠于印尼市场增长，以及Scoreflex TRIO 在新加坡及马来西亚获更广泛采用，亚太地区收入同比上升14.0%至27.3百万美元。欧洲、中东及非洲市场方面，德国、法国及西班牙等直销市场及包括英国、斯洛伐克及捷克共和国在内的分销市场的自有球囊类产品销售表现强劲，带动该区收入上升17.0%至22.4百万美元。尽管受关税因素影响，美国市场收入仍同比上升20.0%至8.0百万美元，主要受冠脉的普通及刻痕球囊，包括高价产品Scoreflex NC球囊，以及外周球囊销量显著上升所推动。而日本及中国境内市场的收入分别为16.1百万美元及9.7百万美元。凭借其广受认可的全球商业化能力，集团与立志走向国际巿场的同业合作，藉此丰富产品组合并开拓额外收入来源。继去年与深圳开立生物医疗科技股份有限公司成功展开合作，在香港及澳门分销血管内超声产品后，集团与该伙伴再度签订独家分销协议，在新加坡及马来西亚分销相关产品。至目前为止，合作范围已进一步扩展至集团旗下位于欧洲的4个直销市场，包括法国、德国、西班牙及瑞士，及其他6个分销市场。性能主导的多元化创新产品组合，提升市场差异化水平截至2025年6月30日，业聚医疗在全球主要司法管辖区拥有逾250项授权专利及已公布专利申请，及逾55款获批产品。期内，集团产品注册及临床试验继续取得进展，包括：- Sapphire 3的美国临床试验进展顺利，预期于2025年第四季度完成病人入组，以支持该产品的FDA纳入CTO适应症，从而与市场上其他传统半顺应性球囊形成差异化；- JADE PLUS及Teleport Glide获得CE标志、Teleport Glide及Scoreflex QUAD获得PMDA批准、COREPASS模组化微导管获得FDA批准、导引导管获得国家药监局批准；- 就Scoreflex TRIO、Sapphire ULTRA、Sapphire NC ULTRA、Sapphire NC 24、JADE PLUS、Teleport XT及Teleport Glide向国家药监局提交注册申请，并就Vascuaid抽吸导管及大管腔延长导管向PMDA提交注册申请。集团拥有庞大的产品管线。在冠状动脉领域，Sapphire PTX紫杉醇药物涂层球囊大约于2025年底在日本展开临床研究；外周方面，JADE Score球囊则预期于2026年向PMDA提交注册申请。合资企业业聚培福在中国境内展开的TricValve临床试验亦取得重大进展，参与医院数量上升，加快了病人入组进度。此外，业聚培福亦正透过"港澳注册药品及医疗器械进入大湾区计划"，积极推动大湾区各大医院采用TricValve。TricValve于2025年7月完成首次在中国境内进行的商业化植入手术，达到重要的里程碑。多区域生产基地缓解地缘政治风险截至2025年6月30日，业聚医疗于中国深圳、荷兰荷佛拉肯，以及德国莱茵河畔魏尔设有生产基地，总年产能约为210万件球囊及支架。自2023年底收购eucatech AG以来，集团已投入资源恢复其生产能力，期内产量逐步提升，以供应销售及临床注册所需产品。2025年8月，集团完成位于中国杭州、旗下最大研发及生产基地的主体结构建设，装修工程预期于下半年展开。该基地计划于2027年投产，届时将新增年产能240万件。钱先生总结说："有见于新兴市场的强劲势头、自研产品陆续成功推出巿场，以及已建立的战略合作，我们对2025年下半年前景保持乐观。除了亚太地区及欧洲、中东及非洲将继续担当主要的增长引擎，我们亦计划将部分市场由分销模式转为直销模式，以强化当地营收能力及市场渗透。欧洲市场将透过于比利时及荷兰设立直销团队加强市场影响力；日本市场则藉新产品上市重拾增长动力；而在中国境内市场，我们则把握政策支持，扩大产品覆盖并加速商业化进程。随着关税争端缓和，美国市场的产品交付亦有望加快。凭借业聚医疗多元化的产品组合、稳健的财务状况及规模经济效益，我们具备优势构建具韧性及竞争力的业务体系，为持份者创造可持续的价值。"关于业聚医疗集团控股有限公司业聚医疗是一家全球医疗器械制造公司，专门生产用于经皮冠状动脉介入治疗（PCI）及经皮腔内血管成形术（PTA）的介入器械。本集团总部位于中国香港，产品销往全球超过70个国家和地区。集团亦积极将业务扩展至结构性心脏病领域。凭借拥有逾20年产品开发经验的内部研发团队，本集团已开发出世界领先的专有技术。如需了解更多详情，请访问集团官网：https://orbusneich.com/ Copyright 2025 亚太商讯 via SeaPRwire.com.

广州，2025年8月15日 - (亚太商讯 via SeaPRwire.com) - 近日，中国电子信息行业联合会公布最新一批获颁数据管理能力成熟度（简称"DCMM"）等级证书企业名单，广发证券获评最高等级五级（优化级）认证，成为行业首家获评最高等级的证券公司，标志着公司在数据管理和应用方面达到国内领先水平，为行业数据管理能力建设树立标杆。《数据管理能力成熟度评估模型》（GB/T 36073-2018）是我国数据管理领域正式发布的首个国家标准。该认证从数据战略、数据治理、数据架构、数据应用等多个维度，全面评估企业的数据管理能力。其中，五级（优化级）作为最高等级，标志着企业的数据管理已形成行业最佳实践，具备强大的示范引领作用。一直以来，广发证券高度重视数据管理能力的建设与提升，将数据视为企业核心资产。公司构建了"战略引领、全员参与、跨部门协同、全生命周期管理"的数据管理体系。通过制定清晰的数据战略规划，完善数据治理组织架构与制度流程，强化数据安全与合规管理，持续提升数据质量与应用效能，公司实现了数据管理从"规范"到"优化"的跨越式发展，为业务创新、客户服务升级及风险管理提供了强有力的数据支撑。广发证券副总经理、首席信息官辛治运表示："公司将以此次获得DCMM五级认证为新的起点，持续深化数据管理能力建设，进一步完善数据治理长效机制，推动数据技术与业务场景的深度融合，并以此为契机，不断提升服务实体经济的质效，为证券行业的数据管理创新与发展贡献更多力量。" Copyright 2025 亚太商讯 via SeaPRwire.com.

HONG KONG, Aug 13, 2025 - (ACN Newswire via SeaPRwire.com) - Essex Bio-Technology Limited (“Essex” or the “Group”, Stock Code: 1061.HK) is pleased to announce that a Biologics License Application (“BLA”) for EB12-20145P (HLX04-O), a recombinant anti-VEGF humanized monoclonal antibody injection, has recently been accepted by the Centre for Drug Evaluation (“CDE”) of the National Medical Products Administration (“NMPA”) in China. The product is jointly developed by the Group and Shanghai Henlius Biotech, Inc. (“Henlius”, Stock Code: 2696.HK) for the treatment of wet age-related macular degeneration (“wet-AMD”) in China.The phase 3 clinical trial of EB12-20145P (HLX04-O) among Chinese patients (“AURA-1”) has successfully reached the primary endpoint in April this year. AURA-1 is a multi-centre, randomised, double-blind, active-controlled, and non-inferiority phase 3 clinical trial which aimed to compare the efficacy and safety of EB12-20145P (HLX04-O) with that of ranibizumab administered by intravitreal injection (“IVT”) in newly diagnosed wet-AMD patients.In addition to AURA-1, the BLA of which has been validated by the NMPA, an international, multi-centre phase 3 clinical study of EB12-20145P (HLX04-O) in patients with wet-AMD is ongoing successively in several European countries, Australia, the United States, and China (“AURA-2”) with last patient last visit completed by January 2025. Moving forward, Essex will continue to strive for excellence by embracing innovation to develop first-in-class and best-in-class products, providing solutions for Tomorrow’s healthcare problems, Today.About wet-AMDAge-related macular degeneration (“AMD”) is one of the leading causes of visual impairment and blindness in the elderly worldwide [1]. According to the World Health Organization (WHO), about 30 million people have suffered from AMD globally, and about half a million people become blind due to AMD each year [2]. Wet age-related macular degeneration (“wet-AMD”) is characterised by the formation of subretinal choroidal neovascularization (CNV) and is responsible for approximately 90% of cases of AMD-related blindness. Due to an aging population, wet-AMD has become a serious social medical problem and indicated a huge burden of unmet need [3]. With the development of treatment for fundus diseases, anti-VEGF drugs are becoming the first-line therapy for the management of wet-AMD [4], and the efficacy and safety of vitreous injection of bevacizumab for wet-AMD have been verified in multiple clinical studies [5-11].About EssexEssex is a bio-pharmaceutical company that develops, manufactures, and commercialises genetically engineered therapeutic b-bFGF, with six commercialised biologics currently marketed in China. Additionally, the Company has a diverse portfolio of commercialised preservative-free unit-dose eye drops, Shilishun (Iodized Lecithin Capsules) and others, which are principally prescribed for wound healing and diseases in Ophthalmology and Dermatology.These products are marketed and sold through approximately 14,000 hospitals, supported by the Company’s 44 regional offices in China. Leveraging its in-house R&D platform in growth factor and antibody technology, Essex maintains a robust pipeline of projects in various clinical stages, covering a wide range of fields and indications.Reference[1] 2020(1).[2] Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004 Nov;82(11):844-51.[3] Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2): e106-116.[4] Li X R, Liu J P. Recognition of anti-VEGF therapy base on the mechanism of VEGF in wet age-related macular degeneration[J]. Zhonghua Shiyan Yanke Zazhi/Chinese Journal of Experimental Ophthalmology, 2012, 30(4):289-292.[5] Tufail A, Patel PJ, Egan C, Hykin P, da Cruz L, Gregor Z, Dowler J, Majid MA, Bailey C, Mohamed Q, Johnston R, Bunce C, Xing W; ABC Trial Investigators. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multi-centre randomized double masked study. BMJ. 2010 Jun 9;340:c2459.[6] Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011 May 19;364(20):1897-908.[7] Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012 Jul;119(7):1399-411.[8] Kodjikian L, Souied EH, Mimoun G, Mauget-Faÿsse M, Behar -Cohen F, Decullier E, Huot L, Aulagner G; GEFAL Study Group. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial. Ophthalmology. 2013 Nov;120(11):2300-9.[9] Krebs I, Schmetterer L, Boltz A, Told R, Vécsei-Marlovits V, Egger S, Schönherr U, Haas A, Ansari-Shahrezaei S, Binder S; MANTA Research Group. A randomized double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol. 2013 Mar;97(3):266-71.[10] Berg K, Pedersen TR, Sandvik L, Bragadóttir R. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology. 2015 Jan;122(1):146-52.[11] Schauwvlieghe AM, Dijkman G, Hooymans JM, Verbraak FD, Hoyng CB, Dijkgraaf MG, Peto T, Vingerling JR, Schlingemann RO. Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration. The BRAMD Study. PLoS One. 2016 May 20;11(5): e0153052. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 14, 2025 - (ACN Newswire via SeaPRwire.com) - Following the lifting of the Black Rainstorm Warning Signal at 11:10am, the Food Expo, Beauty & Wellness Expo, Home Delights Expo, Food Expo PRO and Hong Kong International Tea Fair will reopen at 1:10pm.The Food Expo, Beauty & Wellness Expo, Home Delights Expo will be extended and close at 11pm from 15 August to 17 August, allowing public visitors to enjoy shopping in these fairs—with a single ticket. The Food Expo PRO and Hong Kong International Tea Fair will remain open until 6pm today and tomorrow (14 to 15 August) and until 5pm on Saturday (16 August), enabling trade buyers and exhibitors to continue their business discussions.Admission tickets valid for today may be used for entry on any of the remaining fair days.Sessions 2 and 3 of the International Conference of the Modernization of Chinese Medicine afternoon programme will be resumed in a hybrid format.HKTDC Food Expo PROfoodexpopro.hktdc.comHKTDC Hong Kong International Tea Fairhkteafair.hktdc.comHKTDC Food Expohkfoodexpo.hktdc.comHKTDC Beauty & Wellness Expohkbeautyexpo.hktdc.comHKTDC Home Delights Expohomedelights.hktdc.comThe International Conference of the Modernization of Chinese Medicine (ICMCM)icmcm.hktdc.comMedia enquiriesOgilvy Public Relations:Rex Cheuk+852 5618 9908rex.cheuk@ogilvy.comDaisy Leung+852 9275 7704daisy.leung@ogilvy.comLeanne Pok+852 9379 9694leanne.pok@ogilvy.comHKTDC's Communications and Public Affairs DepartmentStanley So+852 2584 4049stanley.hp.so@hktdc.orgSerena Cheung+852 2584 4272serena.hm.cheung@hktdc.orgClayton Lauw+852 2584 4472clayton.y.lauw@hktdc.orgHKTDC Media Room: http://mediaroom.hktdc.comAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 14, 2025 - (ACN Newswire via SeaPRwire.com) - Weilong Delicious Global Holdings Ltd (“WL Delicious” or the “Company”) and together with its subsidiaries (the “Group”) (Hong Kong stock code: 9985.HK) announced its unaudited interim results for the six months ended 30 June 2025 (the “Reporting Period”).RMBFor the 6 months ended 30 June20252024ChangeRevenue3,483 million2,939 million+18.5%Gross Profit1,642 million1,462 million+12.3%Gross Profit Margin47.2%49.8%-2.6p.p.Net Profit736 million621 million+18.5%Net Profit Margin21.1%21.1%Remain stableInterim Dividend0.18 / ordinary share0.16 / ordinary share+12.5%In the first half of 2025, despite global consumption growth facing general pressure, China remained one of the world’s largest consumer markets. Benefiting from the steady growth momentum of China’s snack food market in recent years, during the Reporting Period WL Delicious kept pace with industry development trends by adhering to its multi-category strategy, focusing on innovation, conducting in-depth consumer insights, accurately capturing market demand, and continuously strengthening its R&D capabilities, while further deepening brand penetration through approaches favored by young consumers, by creating multi-dimensional consumption scenarios and connections through various online and offline brand activities, the Group continuing to enhance its omnichannel coverage and sales network, thereby providing better services and experiences for clients and consumers.During the Reporting Period, WL Delicious' business strategy delivered substantial outcomes, with operational performance continuing to rise steadily, both revenue and net profit recording double-digit growth. In the first half of 2025, the Group achieved a total revenue of RMB3,483 million, representing a year-on-year growth of 18.5% primarily due to the Group’s continuous efforts in strengthening omni-channel development and brand building, as well as optimizing the channel structure during the reporting period. Despite the increase in certain raw material costs during the Reporting Period, which caused the Group's gross profit margin declined by 2.6 percentage points from 49.8% in the corresponding period of the Previous Year to 47.2%; gross profit still rose by 12.3% year-on-year to RMB 1,642.4 million, driven by both revenue growth and the Group’s active enhancement of supply chain efficiency. At the same time, benefiting from the increase in the Group's operating profit, net profit for the Reporting Period grew by 18.5% year-on-year to RMB 736.2 million, while the net profit margin remained at the same level year-on-year at 21.1%.Based on the overall performance during the Reporting Period, the Board of Directors has resolved to the distribution of the interim dividend of RMB0.18 per share, representing a payout ratio of approximately 60%. The dividend is expected to be paid on or about October 20, 2025.In terms of products, the Group adhered to a strategy of multiple categories, making efforts in terms of new products, new flavors, new craftmanship, and new packaging, such as expanding the boundaries of flavor innovation and responding in depth to consumers’ demand for innovative flavors. During the Reporting Period, the Group launched a number of new products such as sesame paste-flavored “Konjac Shuang” and spicy beef-flavored “Kiss Burn”, further expanding and enriching the product portfolio, enhancing product quality, meeting the diverse and personalized consumption needs of the market, and driving a stronger match between product strength and market demand.In terms of brand development, the Group continued to deepen brand penetration through approaches favoured by young consumers, building multi-dimensional consumer scenarios and connections through various online and offline brand activities. For example, the Group partnered with LINLEE to initiate the “Spicy Challenge”, leveraging its best-selling products and buzz to reach more consumers; collaborated with the domestic trend brand Crying Center to launch the “Big Kids Exclusive” series, using holiday marketing to evoke youthful taste memories. In addition, the Group officially announced Mr. WANG Anyu as the spokesperson for its Konjac products, leveraging the influence of celebrities to broaden the channels of communication. This series of measures effectively reached the young customer base and solidified the foundation for the brand’s youthful and fun-oriented development.In terms of distribution channels, the Group continued to advance its offline omni-channel and online all-platform coverage strategy. With the emergence of new channel market practice, the Group kept pace with channel changes, continuously expanding POS network, strengthening the sales team’s execution capability at the POS , collaborating with distributors to upgrade POS services and product availability, in order to drive steady growth in offline POS performance. On traditional e-commerce platforms, the Group also actively expanded its presence, building an all-platform ecosystem to ensure effective synergy with offline channels and to facilitate the implementation of its omni-channel development strategy.In addition, the Group has remained committed to automation upgrades and technological innovation breakthroughs in its production facilities, while accelerating the digital transformation of its business systems. On this basis, the Group has continuously strengthened organisational development and the building of its core talent pipeline, thereby enhancing overall operational efficiency and injecting strong momentum into the sustainable and steady development of its business.Mr. Liu Weiping, Chairman of WL Delicious, stated: "The Group will remain committed to its ‘multi-category’ product strategy, uphold product innovation, continue to strengthen brand building, and further reinforce WL Delicious’ brand image and distinctive positioning as youthful, fun, and creative. At the same time, the Group will actively embrace change, continuously enhance its omnichannel coverage capabilities, and provide consumers with more convenient consumption experiences. Looking ahead, the Group will embrace market changes with a more proactive mindset, continually enhance our competitiveness with better products, higher-quality services, and improved experiences, and create more value for consumers, customers, shareholders, investors, employees, and society as a whole."About Weilong Delicious Global Holdings LtdWEILONG Delicious Global Holdings Limited ("WL Delicious") is an all-in-one spicy snack products enterprise, leading in the research and development, production, and sales of spicy snack foods in China. Based on traditional formulas, WL Delicious started the Chinese seasoned flour products (also commonly known as Latiao industry, created our first Latiao snack in 2001, leading the standards construction of Latiao industry. With our outstanding product development capabilities, the Group has successfully diversified into vegetable products, bean-based products and others, including Konjac Shuang , Fengchi Kelp , XIAO MO NV and others. WL Delicious is a popular snack food brand among young consumers in China. It has an omni-channel sales and distribution network that effectively reaches young consumers. For more information, please visit: https://www.weilongshipin.com/. Copyright 2025 ACN Newswire via SeaPRwire.com.

RAS AL KHAIMAH CITY, UAE, Aug 14, 2025 - (ACN Newswire via SeaPRwire.com) - Ras Al Khaimah International Corporate Centre (RAK ICC) has announced significant amendments to its Foundations Regulations 2019, which took effect on 31 July 2025. The changes represent one of the most substantial updates to the regime since its introduction, reinforcing the UAE's position as a competitive jurisdiction for wealth structuring and long-term asset protection.RAK ICC Foundations are widely recognized for their flexibility, confidentiality, and legal robustness, making them a preferred choice for high-net-worth individuals, entrepreneurs, and family offices, both within the UAE and internationally. These structures are commonly used for succession planning, family governance, and consolidating diverse assets under a single legal entity.The 2025 amendments introduce stronger legal safeguards and improved governance measures which include:Firewall Provisions - Stronger protection from foreign judgments conflicting with RAK ICC Regulations.Three-Year Statute of Limitations - Limits challenges to establishment or asset transfers to three years.Cause of Action Provisions - Creditor fraud claims are limited to the specific asset involved and only if rendering the founder insolvent.Duress and Officer Protections - Nullifies actions taken under foreign legal coercion, preserving internal governance autonomy of a foundation.Strengthened Arbitration Framework - Disputes can be resolved privately with court-level powers.Private Trustee Foundation Provisions - Clarifies asset segregation and fiduciary integrity for property held in trust by a foundation.Assets held within RAK ICC Foundation will now benefit from enhanced firewall provisions, ensuring that foreign judgments conflicting with UAE law cannot be enforced against them. A new three-year limitation period has been established for challenging the formation of a foundation or the transfer of assets into it, providing greater certainty for founders and beneficiaries. The reforms also tighten creditor protection rules by requiring proof of insolvency in fraudulent transfer claims, with liability capped at the value of the disputed asset to prevent overreach into unrelated holdings.In addition, the updated regulations address governance integrity and operational resilience. Officers of a foundation who receive foreign orders inconsistent with RAK ICC law are obligated to disregard them, thereby safeguarding the autonomy of the foundation's decision-making. The framework now explicitly confirms that assets held in trust by a foundation are legally distinct and separate from foundation property, ensuring clear asset segregation. Dispute resolution has also been strengthened, with arbitration provisions expanded to grant tribunals court-like powers, enabling disputes to be resolved efficiently, confidentially, and in line with international best practices.These changes are part of RAK ICC's broader strategy to maintain a forward-looking legal and regulatory environment that meets global standards while catering to the specific needs of its client base. They reflect the jurisdiction's commitment to supporting sophisticated wealth planning strategies that balance control, privacy, and long-term security.By enhancing its Foundations regime, RAK ICC is cementing its position in the UAE as a trusted partner for those seeking secure, adaptable, and internationally compliant solutions for wealth preservation and intergenerational planning.About RAK ICCRas Al Khaimah International Corporate Centre (RAK ICC) is a corporate registry based in Ras Al Khaimah, United Arab Emirates. The organisation provides international business companies and foundations, typically used for private and business structuring, asset consolidation, and succession planning. To date, RAK ICC has incorporated thousands of international companies and supports multi-billion dirhams in structured assets. It serves high-net-worth individuals, entrepreneurs, and businesses seeking flexible and secure solutions for long-term business and wealth management.For media enquiries, contact us at:Phone: +971 7 207 7177Email: info@rakicc.comWebsite: https://www.rakicc.com/contact-us/SOURCE: RAK ICC Copyright 2025 ACN Newswire via SeaPRwire.com.

香港，2025年8月14日 - (亚太商讯 via SeaPRwire.com) - 越秀房地产投资信托基金（「越秀房产基金」，连同越秀房托资产管理有限公司，统称「基金」；股份代号：405）公布其截至2025年6月30日止六个月之中期业绩。越秀房产基金管理团队：主席及非执行董事江国雄先生（中）、执行董事及行政总裁区海晶女士（左）、财务总监关志辉先生（右）2025年中期业绩摘要：- 整体经营稳定，收入总额为人民币9.66亿元（2024年同期：人民币10.34亿元）。- 于2025年6月30日，物业整体出租率为82.2%（2024年同期：84.0%）。- 平均融资成本为3.33%，较年初下降83个基点，剔除汇兑亏损的融资成本同比减少13.5%。- 中期分派每个基金单位约人民币0.0333元，约等于0.0366港元。按年计算的分派收益率为8.42%。广州国金中心：- 广州国金中心综合体录得经营收入为人民币4.86亿元，占基金收入总额50.3%。- 广州国金中心写字楼引进一家财富世界500强背景企业；出租率为82.6%；续约率为70%。- 国金天地期内出租率高达96.4%。- 广州四季酒店平均入住率同比上升1.1个百分点，客房收入创历史同期新高；国金中心雅诗阁服务式公寓平均入住率同比增长1.8个百分点，营业收入亦创历史同期新高。广州越秀金融大厦：- 越秀金融大厦录得经营收入约人民币1.65亿元，占基金收入17.1%，出租率达82.1%。- 租户结构不断优化，新引进优质租户包括一家财富世界500强背景企业，以及一家市值超百亿的期货企业。积极管理融资风险，有效平抑融资成本- 针对2025年上半年到期的人民币5.3亿元短期贷款、21亿港元5年期银团贷款及今年内到期的其他贷款，管理人于2025年上半年完成人民币5.3亿元短期贷款续借，并通过取得人民币17亿元境外贷款和发行人民币10亿元点心债，用于到期贷款的再融资及提前置换，确保流动性风险得到有效管控。- 管理人期内合计引入人民币32.3亿元贷款，并置换境外浮息港元贷款，利用人民币融资相对低位，主动调节融资结构，降低利率市场冲击。2025年上半年末融资利率敞口约为14%，较年初26%收窄12个百分点；平均融资成本为3.33%，较年初4.16%下降83个基点；上半年平均付息率3.92%，同比下降64个基点。剔除汇兑亏损的融资成本约为人民币4.02亿元，同比减少13.5%。- 2025年6月末人民币融资约147.95 亿元，占总体融资72%（2024年同期：人民币融资约84.04 亿元，占总体融资41%）。越秀房产基金主席及非执行董事江国雄先生表示：「2025年上半年，在全球贸易环境波动及经济增长放缓的背景下，中国国内生产总值GDP同比增长5.3%，但企业扩张保守缓慢；零售消费疲弱、酒店公寓房价承压。为应对行业不利因素，我们策略性抢占市场份额，提前推进续租工作，投入资本性改造，提升产品竞争力，有效稳住经营基本面，为中期经营收入提供坚实支撑。同时，融资成本回落也为分派创造有利条件。」国金中心国金中心透过提升产品和优化营运，客户访问量和转化率均录得正向提升，新签13,133平方米。推出4,235平方米带装修单元去化周期仅约十九天，去化率接近九成。引进优质租户包括一家财富世界500强背景企业、一家全球龙头航运企业和一家知名互联网背景文体娱乐企业，合计超过2,200平方米。续租9,099平方米，续租率70%，留存优质租户包括两家财富世界500强背景企业和一家外国领事馆。国金中心入选观点「表现力指数·2025商办资产运营表现」TOP30榜单。国金天地积极打造电子化消费场景，推进悦秀会本地生活平台试点落地，已覆盖12家商户，同时利用大众点评、云闪付等平台多渠道引流，新签和续租合计5,734平方米，续租率97%。出租率为96.4%。期内，中免免税店宣布落户国金天地，预计第三季度开业，成为广州首家且目前唯一的市内免税店。广州四季酒店客房收入和国金中心雅诗阁服务式公寓营业收入分别创历史同期新高。广州四季酒店期内平均入住率为80.1%，同比上升1.1个百分点；平均房价为人民币2,201元，与去年同期相若；每间可供出租客房收入(RevPAR)为人民币1,762元，同比增长0.7%；RevPAR竞争指数为111.7，在奢华酒店竞争群组中始终保持较领先的市场地位。国金中心雅诗阁服务式公寓期内平均入住率为92.3%，同比上升1.8个百分点，平均入住率高于竞争群公寓9.7个百分点；平均房价为人民币1,128元，与去年同期相若；RevPAR为人民币1,041元，同比增长1.5%；RevPAR竞争指数达120.0。越秀金融大厦越秀金融大厦期内新签7,448平方米，包括七家租户扩租合计1,500平方米。推出7,089平方米带装修单元，去化周期约38天，去化率超过六成半。新引进优质租户包括一家财富世界500强背景企业，以及一家市值超百亿的期货企业。受部分租户回迁自有物业办公的影响，续租10,303平方米，续租率42%。留存大面积优质租户包括国际四大之一「德勤」和一家国内龙头综合性资产管理公司。白马大厦白马大厦引入珠三角供应链资源，期内带动新签3,273平方米，实现一楼满租。上半年累计接待165个采批团，累计接待采购商近5,000人次，其中包括来自法国、越南等23个外商团，促成采购金额达人民币1.4亿元。白马大厦依托大湾区国际女装展、广交会等展会促进租户成交，亦成功推出「白马悦境通」跨境电商平台和「白马商学院营销赋能营」系列课程，激活租户数字化运营新动能。财富广场财富广场期内新签2,354平方米，引进优质租户包括一家财富世界500强综合金融集团旗下医疗养老板块的数家企业。续租2,924平方米，续租率76%，留存优质租户包括一家财富世界500强背景企业，亦灵活匹配降本需求调整单元挽留租户。城建大厦城建大厦期内新签7,585平方米，引进一家美容科技企业提升楼内大健康业态氛围。结合租户降本意愿制定挽留方案，优化产品标准匹配租户需求。续租2,090平方米，续租率68%，包括一家全球知名合同研究组织(CRO)的广州办公室。维多利广场维多利广场期内主力租户「优衣库」继续发挥旗舰作用，首发C系列产品，并于3月28日至4月6日落地全国首场「优衣库美好生活市集」、巨型宝可梦及美好生活音乐活动，活动期间达季度客流峰值，带动四月销售额同比增长7%，推动中期期间销售额同比增长0.3%。项目联动餐饮租户，抓住客流高峰提升销售，带动中期期间项目整体销售额同比增长0.6%。上海越秀大厦上海越秀大厦期内续租3,798平方米，续租率39%；新签3,933平方米，迅速填补退租单元。通过更换停车场节能灯管提升场内亮度，项目实现节能效益和服务水平双提升，提高租户满意度。于中期期末，上海越秀大厦出租率为87.2%，同比增加2.6个百分点。武汉物业武汉越秀财富中心期内新签12,395平方米，引进优质租户包括一家全球领先汽车集团成员企业和一家多元化专业服务企业。续租10,884平方米，续租率81%，留存大面积优质租户包括一家财富世界500强背景央企。招商团队透过单元局部微改造、软装提升、打造智能样板间等多种方式优化客户看楼体验，提升客户转化率。星汇维港购物中心期内新签和续租合计3,894平方米，续租率82%。成功引进多家热门餐饮品牌，包括A馆一楼引进网红品牌「达美乐」，带动更多家庭客群。项目开拓夜间消费，利用四楼「悦花园」亮点优势，持续打造「江畔星夜」、「深夜食堂」激发销售新增长点。杭州维多利杭州维多利期内新签1,974平方米，引进一家全层租户。续租6,083平方米，续租率64%，留存优质租户包括一家财富世界500强背景建筑工程企业和一家山西省属国企的浙江分公司。未来展望市场普遍憧憬美联储下半年进一步降息，但路径和幅度仍具不确定性。另一方面，今年是中国「十四五」规划收官之年，各项政策稳字当头，包括适度宽松货币政策和「以旧换新」消费补贴政策，旨在通过扩大内需激发市场活力，因此管理人预期人民币利率将维持较低水平。伴随国内新质生产力加快培育发展和供给侧改革深化推进，管理人预期产业动能继续推陈出新，营商气氛将向好改善。备受瞩目的第十五届全国运动会将于下半年在广州开幕，有望带动商场消费和酒店公寓需求。下半年，管理人将因应经济发展走势动态实施积极、稳健、灵活的租赁策略，敏锐把握潜在机会，持续提升资产组合市场竞争力。管理人将视市场发展预期对融资结构持续检视并进行合理调整，通过各类人民币融资途径，引入低成本人民币融资，以寻求更优融资成本，平滑利率风险。管理人将按计划开展相关资本性改造工程，合理规划和分段改造广州四季酒店客房，围绕产品提升、设备更新和安全保障维度，实现物业保值增值，为项目稳健经营保驾护航。关于越秀房地产投资信托基金越秀房地产投资信托基金（「越秀房产基金」）于2005年12月21日在香港联交所上市，为全球首只投资于中国内地物业的上市房地产投资信托基金。越秀房产基金目前持有的物业组合包括位于广州的广州国际金融中心、白马大厦、财富广场、城建大厦、维多利广场、越秀金融大厦、位于上海的越秀大厦、位于武汉的武汉物业（包括武汉越秀财富中心和星汇维港购物中心）、位于杭州的维多利商务中心以及位于香港的越秀大厦共10项高素质物业，物业产权面积共约118.4万平方米，分别位于中国广州市、上海市、武汉市、杭州市及香港市的核心商业区域。物业类型包括甲级写字楼、商业综合体、零售商业、酒店、服务式公寓、服装专业市场等。传媒查询:纵横财经公关顾问有限公司李惠儿电话: +852 2864 4834电邮：sprg_yx@sprg.com.hk梁家仪电话: +852 2114 4172张铭伊电话: +852 2864 4903网址:http://www.sprg.com.hk Copyright 2025 亚太商讯 via SeaPRwire.com.

香港，2025年8月14日 - (亚太商讯 via SeaPRwire.com) - 云顶新耀今日宣布，中国台湾地区药政主管部门（TFDA）已正式受理维长宁（艾曲莫德，中国台湾地区商品名："維長寧"）用于治疗中重度活动性溃疡性结肠炎（UC）患者的新药上市许可申请（NDA）。这一进展标志着艾曲莫德继在中国澳门、新加坡和中国香港获批以及韩国NDA获正式受理之后，在亚洲市场的准入取得又一重大里程碑。中国国家药品监督管理局也于2024年12月正式受理艾曲莫德（维适平(R)）的新药上市申请，预计将在今年年底或明年年初获批。艾曲莫德是一款针对溃疡性结肠炎，每日一次的口服一线治疗药物，能够强效实现肠道黏膜愈合，且使用便捷，并具有良好的安全性特征。黏膜愈合是国内外溃疡性结肠炎临床指南一致认定的溃疡性结肠炎治疗目标。溃疡性结肠炎患者尽早实现黏膜愈合，可大幅降低疾病复发率、住院率、结直肠切除手术率和结直肠癌发生风险。艾曲莫德已被纳入2024年美国胃肠病学协会（AGA）临床实践指南, 推荐作为溃疡性结肠炎的一线治疗。2025年，艾曲莫德获得2025年美国胃肠病学会（ACG）成人UC临床指南的一线治疗推荐，进一步印证了其全球专业共识下的临床价值。云顶新耀首席执行官罗永庆先生表示："此次在中国台湾地区NDA申请的正式受理，是维长宁亚洲商业化进程中的又一重要进展。随着亚洲地区溃疡性结肠炎患者人数持续增长，临床上存在巨大未满足需求。仅在中国，2024年溃疡性结肠炎患者数量约为80万人，预计到2030年将达100万人。患者面临长期治疗与生活质量的双重挑战。此次受理充分体现了对维长宁临床价值的高度认可。我们将继续加快这一创新疗法在中国大陆及亚洲其他市场的上市进程，提升可及性，帮助患者实现长期疾病控制并改善生活质量。"本次申请基于ELEVATE UC III期注册研究（ELEVATE UC 52和ELEVATE UC 12）和ENLIGHT研究（ES101002）的结果。ELEVATE UC III期注册研究显示，在既往常规治疗、生物制剂或JAK抑制剂治疗失败或不耐受的中重度活动性溃疡性结肠炎患者中，每日一次2mg艾曲莫德在第12周和第52周均显示卓越且持久的临床缓解和内镜下深度黏膜愈合，且安全性良好，与既往研究一致。同时，ENLIGHT研究作为迄今最大规模的亚洲中重度UC III期注册临床研究，在中国大陆、中国台湾及韩国开展，共纳入340名患者。研究结果显示，艾曲莫德在诱导期和维持期均取得了显著且具有统计学意义的疗效优势，为其在亚洲人群中的应用提供了有力证据支持。作为云顶新耀在自身免疫性疾病领域的重磅产品，艾曲莫德已于2024年被纳入粤港澳大湾区内地9市临床急需进口港澳药品医疗器械目录，在大湾区先行使用，惠及UC患者，并成为公司第三款商业化新药。今年3月，云顶新耀已启动艾曲莫德在嘉善工厂的本地化生产建设项目，以支持其在大中华区及亚洲其他市场的供应与商业化落地。 Copyright 2025 亚太商讯 via SeaPRwire.com.

阿联酋拉斯海马市, 2025年8月14日 - (亚太商讯 via SeaPRwire.com) - 阿勒哈伊马国际公司注册中心（RAK ICC）宣布对其2019年《基金会条例》进行重大修订，新规已于2025年7月31日生效。此次修订是该制度自推出以来最为重要的更新之一，进一步巩固了阿联酋作为财富架构与长期资产保护竞争性司法辖区的地位。RAK ICC基金会因其灵活性、保密性及法律稳健性而广受认可，成为阿联酋国内外高净值人士、企业家及家族办公室的首选架构工具。这类结构通常用于继承规划、家族治理，以及将多元化资产整合于单一法律实体之下。2025年的修订引入了更强的法律保障及改进的治理措施，包括：1. 防火墙条款 —— 对与RAK ICC法规相冲突的外国判决提供更强有力的保护。2. 三年诉讼时效 —— 将对基金会设立或资产转移提出异议的时限限制为三年。3. 诉因条款 —— 债权人欺诈索赔仅限于涉案的特定资产，且仅在该行为导致创办人资不抵债时才适用。4. 胁迫与高管保护 —— 宣告在外国法律胁迫下采取的行为无效，从而保障基金会内部治理的自主权。5. 强化仲裁机制 —— 允许通过具备法院级权力的私下仲裁方式解决争议。6. 私人受托基金会条款 —— 明确基金会作为受托人持有财产时的资产隔离及受信义务的完整性。在RAK ICC基金会持有的资产现将享有更强的防火墙保护，确保与阿联酋法律相冲突的外国判决无法对其执行。新规设立了三年的时效期，用于限制对基金会成立或资产转入的质疑，为创办人及受益人提供更大的确定性。改革还收紧了债权人保护规则，在欺诈性转让索赔中须证明创办人资不抵债，并将责任限定在争议资产的价值范围内，以防涉及无关财产。此外，修订后的法规着重维护治理完整性和运营韧性。基金会高管在收到与RAK ICC法律不一致的外国命令时，必须予以忽略，从而保障基金会决策的自主权。新框架明确规定，基金会作为受托人持有的信托财产在法律上独立且与基金会自有财产分离，确保资产隔离的清晰性。争议解决机制也得到了强化，扩大的仲裁条款赋予仲裁庭类似法院的权力，使争议能够高效、保密地解决，并符合国际最佳实践。这些变化是RAK ICC维护前瞻性法律与监管环境整体战略的一部分，旨在满足全球标准的同时兼顾客户群体的特定需求。这也体现了该司法辖区在支持兼顾控制、隐私与长期安全的高端财富规划策略方面的承诺。通过强化其基金会制度，RAK ICC正巩固其在阿联酋的地位，成为寻求安全、灵活且符合国际合规标准的财富保全与跨代规划解决方案的可信赖合作伙伴。关于RAK ICC阿勒哈伊马国际公司注册中心（Ras Al Khaimah International Corporate Centre，简称RAK ICC）是一家总部位于阿联酋阿勒哈伊马的公司注册机构。该机构提供国际商业公司及基金会架构，通常用于私人及商业结构设计、资产整合以及继承规划。截至目前，RAK ICC已注册成立数千家国际公司，并为数十亿迪拉姆的结构化资产提供支持。其服务对象包括高净值人士、企业家及寻求灵活、安全的长期商业与财富管理方案的企业。媒体咨询请联系我们:Phone: +971 7 207 7177Email: info@rakicc.comWebsite: https://www.rakicc.com/contact-us/来源: RAK ICC Copyright 2025 亚太商讯 via SeaPRwire.com.

香港，2025年8月14日 - (亚太商讯 via SeaPRwire.com) - 中国辣味休闲食品行业龙头企业，卫龙美味全球控股有限公司（"卫龙美味"或"集团"）及附属公司（"集团"）（ 香港联交所股票代码：09985）公布截至2025年6月30日止六个月（"期内"）之中期业绩。人民币截至6月30日止六个月2025年2024年变动收入34.83亿29.39亿+18.5%毛利16.42亿14.62亿+12.3%毛利率47.2%49.8%-2.6个百分点期内净利润7.36亿6.21亿+18.5%净利润率21.1%21.1%保持稳定中期股息0.18元/普通股0.16元/普通股+12.5%2025年上半年，在全球消费增长普遍承压下，中国消费市场依然是全球最大消费市场之一。 得益于中国休闲食品市场近年来呈现出稳健的增长态势，报告期内，卫龙美味紧跟行业发展趋势，坚持多品类产品策略，聚焦创新，深度开展消费者洞察，精准捕捉市场需求，持续强化研发实力，并持续以年轻人喜爱的方式深化品牌渗透，通过各种线上线下的品牌活动搭建多维消费场景链接深化品牌渗透，持续推进全渠道覆盖能力和销售网络，进而为客户及消费者提供更好的服务和体验。报告期内，卫龙美味经营策略成效彰显，业绩持续稳健攀升，收入与净利润均录得双位数增长。2025年上半年实现总收入34.83亿元（人民币，下同），同比增长18.5%，主要由于集团期内持续加强全渠道和品牌建设，并优化渠道结构。尽管报告期内部分原材料成本上涨导致集团毛利率由去年同期的49.8%下降2.6个百分点至47.2%，但在收入增长及集团积极提升供应链效率的共同因素驱动下，毛利仍同比增长12.3%至16.42亿元。同时受惠于集团经营利润的提升，集团期内净利润同比增长18.5%至7.36亿元；净利润率得以维持去年同期水平，为21.1%。基于期内整体绩效表现，集团董事会决议派发2025年中期股息每股人民币0.18元，派息比率约为60%，预计派付股息日期为2025年10月20日或前后。产品方面，集团坚持多品类产品策略，从新产品、新口味、新工艺、新包装等维度发力，如拓展风味创新边界，深度回应消费者对创新口味的需求。2025上半年，集团先后先后推出了麻酱口味"魔芋爽"以及麻辣牛肉口味"亲嘴烧"等多个新品，进一步拓展并丰富产品组合，提升产品品质，满足市场多元化及个性化的消费需求，驱动产品力与市场需求匹配。品牌建设方面，集团持续以年轻人喜爱的方式深化品牌渗透，透过各种线上线下的品牌活动搭建多维消费场景链接，譬如联合林里柠檬茶发起"爆辣挑战"，凭借爆款销量与话题效应触达更多消费者；携手国潮品牌哭喊中心推出"大儿童专属"系列，借节日营销勾起青春味觉记忆。此外，集团于报告期内官宣王安宇担任魔芋爽代言人，借力明星影响力拓宽传播路径。集团的一系列举措有效触达年轻客群，夯实了品牌年轻化与趣味化的发展根基。渠道方面，集团持续推进线下全渠道、线上全平台覆盖策略。随着各种新兴渠道业态的兴起，集团紧跟渠道变化，持续拓展终端网点，强化销售团队终端执行力，并联合经销商持续提升终端的服务能力和产品铺市率，从而有力推动线下终端业绩稳步增长。在线上领域，集团同样积极布局，构建全平台生态体系，确保与线下渠道形成有效联动，助力全渠道发展战略落地。此外，集团始终致力于生产设施的自动化升级与技术创新突破，同步加快各业务系统的数字化转型进程。在此基础上，集团不断强化组织发展与核心人才梯队建设，以此全面提升公司整体运营效能，为业务的持续稳健发展注入强劲动力。卫龙美味董事长刘卫平先生表示："集团将始终坚守"多品类"产品策略，坚持产品创新，持续加码品牌建设力度，不断强化卫龙"年轻、有趣、有创意"的品牌形象与独特调性。与此同时，集团积极拥抱变化，持续加强全渠道的覆盖能力，为消费者提供更便捷的消费体验。展望未来，集团将以更积极、更主动的心态拥抱市场的变化，以更好的产品、更优质的服务和体验不断提升我们的竞争力，持续为消费者、客户、员工、投资人及社会创造更大的价值。"关于卫龙美味全球控股有限公司卫龙美味全球控股有限公司（"卫龙美味"）是中国领先的集研发、生产及销售为一体的辣味休闲食品企业，拥有强劲的增长势头和颇具影响力的品牌。 卫龙美味以传统美食为基础开创了中国调味面制品（俗称辣条）行业，于2001年开创出第一根辣条，并引领了辣条行业标准建设。 凭借出众的品类拓展能力，本集团已成功扩展至蔬菜制品、豆制品及其它产品等品类，推出了包括魔芋爽、风吃海带、小魔女等大单品。 卫龙美味是倍受中国年轻消费者喜爱的休闲食品品牌，拥有有效触达年轻消费者的全渠道销售及经销网络。 如欲获得更多信息，请浏览： https：//www.weilongshipin.com/。 Copyright 2025 亚太商讯 via SeaPRwire.com.

东京, 2025年8月14日 - (亚太商讯 via SeaPRwire.com) - TANAKA PRECIOUS METAL GROUP Co., Ltd.（总公司：东京都中央区、执行总裁：田中 浩一朗）决定与株式会社JEPLAN（总公司：神奈川县川崎市、代表取缔役 社长兼执行总裁：高尾 正树、以下简称“JEPLAN”） 开展业务合作，以减少TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd.在贵金属回收工艺中的CO₂排放，并推进有机物的资源化再利用。本次合作由长期致力于在贵金属领域推动循环经济（Circular Economy）的TANAKA、以及在塑料领域持续精进技术的的JEPLAN携手推动，旨在实现脱碳化和循环型社会的目标。TANAKA迄今为止为实现循环型社会所方面的努力TANAKA自1885年创业以来，作为贵金属行业的领军企业长年致力于稀缺资源贵金属的回收。其中受客户委托回收的工序废弃物中，对于以有机物（塑料）为主要成分、且附着或吸附有贵金属的工序废弃物，一直以来通过烧成工艺去除有机物，并从剩余的灰烬中回收贵金属。尽管这种烧成处理方式能够有效去除环境管制物质，但在去除过程中有机物燃烧所产生的CO₂排放，成为实现脱碳社会的课题。通过与JEPLAN业务合作、革新贵金属回收工艺JEPLAN已建立了针对聚对苯二甲酸乙二醇酯（PET，一种塑料）的创新化学回收技术。为了解决上述CO₂排放量的课题，TANAKA通过与JEPLAN的业务合作，除了传统的采用烧成的贵金属回收工艺以外，还在考虑未来利用化学回收处理的工艺。预期的化学回收处理的对象为注射器、擦拭布等塑料。预计通过该技术，贵金属回收工艺中的CO₂排放量可控制在以往的10%左右。此外，该新工艺不仅可以回收贵金属，也可以实现塑料再生，TANAKA与JEPLAN将充分发挥各自在专业领域的优势，共同为实现脱碳和循环型社会贡献力量。 株式会社JEPLAN总公司所在地：神奈川县川崎市川崎区扇町12-2成立：2007年1月代表人：代表取缔役 社长兼执行总裁 高尾 正树主要业务内容：PET化学回收技术相关业务（对象：PET塑料瓶、聚酯）等官方 HP：http://www.jeplan.co.jpJEPLAN集团以“循环一切”为使命，致力于实现循环经济。通过使用创新的PET化学回收技术，将废弃PET（PET塑料瓶、聚酯纤维等）分解至分子水平并去除杂质，使其重新生成与石油基材料同等品质的再生材料。通过使用这项创新技术致力于回收再利用，实现有限资源的循环，并为减少CO₂排放量做出贡献。关于TANAKATANAKA自1885 年（明治18年）创业以来，营业范围以贵金属为中心，并以此展开广泛活动。公司在日本国内拥有非常可观的贵金属交易量, 长年以来不遗余力地进行工业用贵金属制品的制造和销售，以及提供作为宝石饰品及资产的贵金属商品。并且，作为贵金属相关的专家集团，日本国内外的各集团公司进行制造、销售以及技术一体化，携手合作提供产品及服务。2024年度（截至2024年12月)集团总营业额为8,469亿日元，拥有5,591名员工。产业事业全球网站https://www.tanaka.com.cn产品咨询表TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd.https://www.tanaka.com.cn/inquiries-on-industrial-products/新闻媒体咨询处TANAKA PRECIOUS METAL GROUP Co., Ltd.https://www.tanaka.com.cn/inquiries-for-media/新闻稿: https://www.acnnewswire.com/docs/files/20250814_CN.pdf Copyright 2025 亚太商讯 via SeaPRwire.com.

HONG KONG, Aug 14, 2025 - (ACN Newswire via SeaPRwire.com) - As the Black Rainstorm Warning Signal was issued at 7:50am, the opening of Food Expo, and the concurrent Food Expo PRO, Hong Kong International Tea Fair, Beauty & Wellness Expo and Home Delights Expo, will be postponed. The opening ceremony originally scheduled for 10:30am, is cancelled. The International Conference of the Modernization of Chinese Medicine will be accessible via livestream.The organiser will make appropriate arrangements to ensure the safety of those already at the venue and will closely monitor the weather conditions. The organiser will open the Food Expo, Food Expo PRO, Hong Kong International Tea Fair, Beauty & Wellness Expo and Home Delights Expo two hours after the Black Rainstorm Warning Signal is cancelled.HKTDC Food Expo PROfoodexpopro.hktdc.comHKTDC Hong Kong International Tea Fairhkteafair.hktdc.comHKTDC Food Expohkfoodexpo.hktdc.comHKTDC Beauty & Wellness Expohkbeautyexpo.hktdc.comHKTDC Home Delights Expohomedelights.hktdc.comThe International Conference of the Modernization of Chinese Medicine (ICMCM)icmcm.hktdc.comMedia enquiriesOgilvy Public Relations:Rex Cheuk+852 5618 9908rex.cheuk@ogilvy.comDaisy Leung+852 9275 7704daisy.leung@ogilvy.comLeanne Pok+852 9379 9694leanne.pok@ogilvy.comHKTDC's Communications and Public Affairs DepartmentStanley So+852 2584 4049stanley.hp.so@hktdc.orgSerena Cheung+852 2584 4272serena.hm.cheung@hktdc.orgClayton Lauw+852 2584 4472clayton.y.lauw@hktdc.orgHKTDC Media Room: http://mediaroom.hktdc.comAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Follow us on @hktdc and LinkedIn Copyright 2025 ACN Newswire via SeaPRwire.com.

香港，2025年8月13日 - (亚太商讯 via SeaPRwire.com) - 亿胜生物科技有限公司（"亿胜生物"或"集团"，股票代码：1061.HK）欣然宣布，集团针对重组抗VEGF眼内注射液EB12-20145P（HLX04-O）的上市注册申请（"BLA"）最近已被中国国家药品监督管理局（"NMPA"）药品审评中心（"CDE"）受理。该产品由集团与上海复宏汉霖生物技术股份有限公司（"复宏汉霖"，股票代码：2696.HK）合作开发，用于治疗湿性年龄相关性黄斑变性（wet age-related macular degeneration, "wet-AMD"）。此注射液EB12-20145P（HLX04-O）在中国患者中开展的III期临床研究（"AURA-1"）已于今年4月成功达到主要研究终点。AURA-1为一项多中心、随机、双盲、阳性对照的非劣效III期临床研究，旨在比较EB12-20145P（HLX04-O）与雷珠单抗玻璃体内注射（IVT）治疗新诊断的wet-AMD患者的有效性和安全性。除其BLA已获NMPA受理申请的AURA-1外，EB12-20145P（HLX04-O）的一项国际多中心III期临床研究（AURA-2）也在欧洲多个国家、澳大利亚、美国和中国顺利开展，AURA-2最后一名患者的最后一次访视已在2025年1月完成。未来，亿胜生物将不懈追求卓越，拥抱创新，持续推动对同类首创(First-in-class)与同类最优(Best-in-class)产品的创新研发，以满足未来更多的临床及商业化需求。关于湿性年龄相关性黄斑变性年龄相关性黄斑变性（AMD）是造成老年人视力损害和不可逆失明的主要原因之一[1]，根据世界卫生组织报告，全球约有3000万AMD患者，每年约有50万人因为AMD而致盲[2]。AMD致盲患者中，以脉络膜新生血管（CNV）为特征的湿性年龄相关性黄斑变性（wet-AMD）比例高达90%。随着老年人口比例的不断上升，wet-AMD已经成为一个日益严重的社会医学问题，存在着巨大的未满足的临床需求[3]。随着眼底治疗方法的突破与发展，抗VEGF药物已成为wet-AMD的一线疗法[4]，贝伐珠单抗玻璃体腔注射治疗wet-AMD的有效性和安全性也已在多项临床研究中得到验证[5-11]。关于亿胜生物（股票代码﹕1061.hk）亿胜生物是一间专注于研发、生产和销售基因工程药物b-bFGF的生物制药企业，拥有包括贝复舒(R)、贝复济(R)、贝复新(R)在内的六种基因工程药物在中国上市销售。此外，公司还拥有包含一系列不含防腐剂单剂量滴眼液和适丽顺(R)卵磷脂络合碘胶囊等的多元化产品组合，主要应用于眼科及皮肤科处方药领域的创伤修复及疾病治疗。这些产品在公司于中国的44个区域办事处的支持下，在逾14,000家医院进行营销和销售。依托自身在生长因子和抗体技术领域的研发平台，亿胜生物在多个临床阶段拥有强大的项目管线，涵盖广泛的领域和适应症。参考文献[1] 欧阳灵艺, 邢怡桥. 抗VEGF药物在湿性年龄相关性黄斑变性中的应用进展[J]. 国际眼科杂志, 2020(1). [2] Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004 Nov;82(11):844-51. [3] Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2): e106-116. [4] Li X R, Liu J P. Recognition of anti-VEGF therapy base on the mechanism of VEGF in wet age-related macular degeneration[J]. Zhonghua Shiyan Yanke Zazhi/Chinese Journal of Experimental Ophthalmology, 2012, 30(4):289-292. [5] Tufail A, Patel PJ, Egan C, Hykin P, da Cruz L, Gregor Z, Dowler J, Majid MA, Bailey C, Mohamed Q, Johnston R, Bunce C, Xing W; ABC Trial Investigators. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multi-centre randomized double masked study. BMJ. 2010 Jun 9;340:c2459. [6] Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011 May 19;364(20):1897-908. [7] Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012 Jul;119(7):1399-411. [8] Kodjikian L, Souied EH, Mimoun G, Mauget-Faÿsse M, Behar -Cohen F, Decullier E, Huot L, Aulagner G; GEFAL Study Group. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial. Ophthalmology. 2013 Nov;120(11):2300-9. [9] Krebs I, Schmetterer L, Boltz A, Told R, Vécsei-Marlovits V, Egger S, Schönherr U, Haas A, Ansari-Shahrezaei S, Binder S; MANTA Research Group. A randomized double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol. 2013 Mar;97(3):266-71.[10] Berg K, Pedersen TR, Sandvik L, Bragadóttir R. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology. 2015 Jan;122(1):146-52. [11] Schauwvlieghe AM, Dijkman G, Hooymans JM, Verbraak FD, Hoyng CB, Dijkgraaf MG, Peto T, Vingerling JR, Schlingemann RO. Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration. The BRAMD Study. PLoS One. 2016 May 20;11(5): e0153052. Copyright 2025 亚太商讯 via SeaPRwire.com.

Ottawa, Ontario--(ACN Newswire via SeaPRwire.com - August 13, 2025) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company"), a leading Canadian graphite developer advancing high-grade projects in Québec, is pleased to announce the resumption of work on the Environmental and Social Impact Assessment ("ESIA") for its 100%-owned Lac Knife flake graphite project located near Fermont, in the province's prolific iron ore mining district.The Company has formally re-engaged IOS Geosciences Inc. ("IOS"), a leading Québec-based geological consulting firm and former general contractor on the ESIA, to complete a total of sixteen (16) technical reports required for submission to Québec's environmental and natural resource authorities. These reports represent a major step in advancing the Lac Knife project toward permitting and the goal of mine construction.The ESIA program, initially launched in 2020, involves multidisciplinary technical evaluations and environmental baseline work conducted across 2020 and 2021. Finalization was delayed due to funding constraints but is now back on track. Report completion is estimated by early 2026, with submissions planned shortly thereafter to the Québec Ministry of Sustainable Development, Environment, and the Fight Against Climate Change ("MDDELCC"), as well as the Ministry of Natural Resources and Forests ("MRNF").The sixteen (16) technical reports in progress cover critical permitting areas, including:Condemnation and pit wall drillingAcid-generating potential analysisGeotechnical drilling and soil mechanicsSoil geochemistry and chemistry baselineLake-bottom geochemical and surface water quality surveysGroundwater habitat assessment and follow-upCaribou habitat assessment and follow-upGeometallurgical and graphite flake characterizationThese comprehensive studies are essential for satisfying Québec's rigorous environmental and social licensing requirements and underscore Focus Graphite's commitment to environmental stewardship and Indigenous engagement through project development.In parallel, Focus has also authorized IOS proceed with geochemical analysis of over 1,000 split and pulverized drill core samples collected from its 2022 exploration drilling program at the Lac Tétépisca ("Tétépisca") graphite project. The samples, targeting the Southwest MOGC and West Limb geophysical (MAG-EM) conductors, will undergo carbon and sulfur determinations at certified laboratories.Upon receipt of assays, IOS will finalize and submit the corresponding technical reports covering 14,900.5 metres of core drilling from 74 holes to the MRNF. An updated Canadian Institute of Mining, Metallurgy and Petroleum ("CIM") and National Instrument ("NI") 43-101 compliant Mineral Resource Estimate ("MRE") for the Manicouagan-Ouest Graphitic Corridor ("MOGC") graphite deposit is anticipated in Fall 2025, which will further define Tétépisca's development potential alongside Lac Knife."Resuming the ESIA is a pivotal milestone that moves us closer to full permitting and our goal of mine development at Lac Knife," said Dean Hanisch, CEO of Focus Graphite. "With most fieldwork and laboratory studies already complete, we're in a strong position to finalize this critical stage efficiently. At the same time, initiating assay work at Tétépisca to support an upgraded mineral resource estimate reflects our commitment to building value across our entire Québec asset base."The Company also announced the grant of incentive stock options as compensation to its directors, officers, employees, and consultants. Options to purchase up to 4,215,000 Common Shares of the Company have been granted at an exercise price of $0.14 per share. The options expire on 13 August, 2030. Additionally, the Company has granted 1,350,000 restricted stock units ("RSUs") to officers, directors, and consultants of the Company under the terms of the Company's restricted share unit and equity incentive plan (the "RSU and EIP Plan"). Each RSU entitles the holder to acquire one common share of the Company after the vesting period in accordance with the Plan.Qualified PersonsThe technical content disclosed in this news release was reviewed and approved by Réjean Girard, P.Geo. (QC), President of IOS Geosciences Inc., a consultant to the Company, and a qualified person as defined under National Instrument NI-43-101.About Focus Graphite Advanced Materials Inc. Focus Graphite Advanced Materials is redefining the future of critical minerals with two 100% owned world-class graphite projects and cutting-edge battery technology. Our flagship Lac Knife project stands as one of the most advanced high-purity graphite deposits in North America, with a fully completed feasibility study. Lac Knife is set to become a key supplier for the battery, defense, and advanced materials industries.Our Lac Tétépisca project further strengthens our portfolio, with the potential to be one of the largest and highest-purity and grade graphite deposits in North America. At Focus, we go beyond mining - we are pioneering environmentally sustainable processing solutions and innovative battery technologies, including our patent-pending silicon-enhanced spheroidized graphite, designed to enhance battery performance and efficiency.Our commitment to innovation ensures a chemical-free, eco-friendly supply chain from mine to market. Collaboration is at the core of our vision. We actively partner with industry leaders, research institutions, and government agencies to accelerate the commercialization of next-generation graphite materials. As a North American company, we are dedicated to securing a resilient, locally sourced supply of critical minerals - reducing dependence on foreign-controlled markets and driving the transition to a sustainable future.For more information on Focus Graphite Inc. please visit http://www.focusgraphite.comInvestors Contact: Dean HanischCEO, Focus Graphite Inc.dhanisch@focusgraphite.com+1 (613) 612-6060Jason LatkowcerVP Corporate Developmentjlatkowcer@focusgraphite.comCautionary Note Regarding Forward-Looking StatementsCertain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could," "intend," "expect," "believe," "will," "projected," "estimated," and similar expressions, as well as statements relating to matters that are not historical facts, are intended to identify forward-looking information and are based on the Company's current beliefs or assumptions as to the outcome and timing of such future events.In particular, this press release contains forward-looking information regarding, among other things, the completion and submission of the sixteen technical reports required for the Lac Knife Environmental and Social Impact Assessment, the anticipated timeline for ESIA report submission and permitting, the initiation and results of geochemical analyses at the Lac Tétépisca project, the anticipated updated NI 43-101 Mineral Resource Estimate for the Tétépisca deposit, the Company's positioning as a near- and long-term secure supplier of specialty graphite materials, and the potential geopolitical significance of Canadian graphite supply.Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, risks related to market conditions, regulatory approvals, changes in economic conditions, the ability to raise sufficient funds on acceptable terms or at all, operational risks associated with mineral exploration and development, and other risks detailed from time to time in the Company's public disclosure documents available under its profile on SEDAR+.The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties, and assumptions contained herein, investors should not place undue reliance on forward-looking information.Neither TSX Venture Exchange nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/262450 Copyright 2025 ACN Newswire via SeaPRwire.com.

Kangji Medical Holdings Limited and Knight Bidco Limited today jointly announced the pre-conditional proposal for the privatisation of Kangji Medical Holdings Limited by way of a scheme of arrangement (the “Proposal”).Proposed privatisation of Kangji Medical Holdings LimitedThe Cancellation Price of HK$9.25 per share represents a 21.7% premium over the closing price on 30 June, 2025, being the Undisturbed Date, a 47.3% premium over the 360-trading day average closing price up to and including the Undisturbed Date, and exceeds the highest closing price as quoted on the Stock Exchange since 2022The proposed privatisation will be effected by way of a scheme of arrangement; the Offeror Concert Parties collectively hold 74.75% shares in the Company; an Irrevocable Undertaking has been received from one institutional shareholder to vote in favour of the ProposalThe Proposal presents shareholders with certainty over their ability to monetise their interests in Kangji Medical Holdings Limited, following a period of sustained pressure on trading prices and limited liquidityHONG KONG, Aug 13, 2025 - (ACN Newswire via SeaPRwire.com) - Aug 12 2025, Kangji Medical Holdings Limited (“Kangji Medical” or the “Company”, Stock Code: 9997.HK) and Knight Bidco Limited (the “Offeror”) today jointly announced a privatisation proposal. The parties intend to implement the privatisation of the Company by way of a scheme of arrangement, with a view to enabling the Company to focus on long-term strategic decisions, such as longer-term business investment in R&D and operations enhancements.Upon completion of the Proposal, the Company will become a wholly-owned subsidiary of the Offeror, and the listing of the Shares will be withdrawn from the Stock Exchange.The Offeror is owned by a consortium comprising Mr. Zhong and Ms. Shentu (the Founders), the TPG Entities, NewQuest V and Al-Rayyan Holding. Rationale for the ProposalDue to the long-term underperformance in the trading prices and trading liquidity of the Shares, the ability of the Company to raise funds from the equity market has been significantly limited. In addition, the Company has to incur administrative, compliance and other listing related costs and expenses for maintaining the listing status. Accordingly, there are limited benefits for the Company to maintain its listing status.In light of intensifying competition in domestic market and ongoing regulatory uncertainties, and in order to achieve sustainable growth, the Company's long-term strategy requires significant investment which could create short-term pressure on the Company’s financial performance. It is anticipated that additional resources need to be allocated to areas including sales and marketing, investment in research, development, and commercialisation, and the Company’s market expansion outside of China.Considering this, and the listing-related costs, there are limited benefits for Kangji Medical to maintain its listing status. In addition, the implementation of the Proposal will alleviate pressure on Kangji Medical’s short-term financial performance, which enables better focus on strategic objectives. It is anticipated that additional resources will need to be allocated for its future sustainable growth.Furthermore, the Proposal provides minority shareholders an attractive opportunity to realise compelling returns amid market volatility, industry and macro uncertainties, and the limited liquidity of the Shares.Knight Bidco Limited’s proposal offers a timely solution to Kangji Medical and its shareholders. Its proposal to privatise Kangji Medical will:(a) reduce Kangji Medical’s administrative, compliance and other listing related costs;(b) relieve Kangji Medical from the pressure associated with short-term performance metrics and enable Kangji Medical to focus on long-term strategic decisions (such as longer-term investment in R&D and operations enhancements which might incur short-term losses); and(c) present shareholders with certainty over their ability to monetise their interests in Kangji Medical at an attractive premium to the undisturbed share price.In summary, the Offeror believes that a take-private transaction is the strategic alternative that provides immediate and most compelling value for all shareholders, while also avoiding exposure to uncertain market conditions.Overview of the ProposalThe proposal sets out a Cancellation Price of HK$9.25 per share, valuing the company at approximately US$1.4 billion on an equity value basis.[1]The Offeror has indicated the Cancellation Price is final and will not be increased further.The Cancellation Price reflects:A 21.7% premium over the closing price on the Undisturbed Date (being 30 June, 2025).A 47.3% premium over the closing price of 360-trading day average price up to and including the Undisturbed Date.An 84.6% premium over the 52-week closing low (HK$5.01) up to and including the Undisturbed Date.A Cancellation Price above the highest closing price as quoted on the Stock Exchange since 2022 (HK$8.66).The Cancellation Price has taken into account, among other things, the recent and historical prices of the Shares traded on the Stock Exchange, publicly available financial information of the Company and with reference to other similar privatisation transactions in Hong Kong in recent years.The Proposal is subject to satisfaction of the Pre-Conditions by the Pre-Condition Long Stop Date (being 31 January, 2026) and the Conditions by the Long Stop Date (being 30 April, 2026). The Company will appoint an independent financial adviser (the “IFA”) to advise the committee of directors who are considered independent for the purposes of the Proposal (the “Independent Directors”) for the purposes of making a recommendation to shareholders in connection with the Proposal. Details of the Proposal including the Independent Directors’ final recommendation on the Proposal and the IFA’s advice will be included in the Scheme Document, expected to be dispatched to shareholders in due course.Scheme MeetingDetails of the Scheme Meeting to be convened will be contained in the Scheme Document which is expected to be dispatched to shareholders in due course.There are several pre-conditions and conditions as set out in the Joint Announcement, including regulatory approvals, shareholders approval and compliance with other legislative requirements.Irrevocable UndertakingAn Irrevocable Undertaking has been received from one institutional shareholder to vote in favour of the Proposal. Further details are available in the Joint Announcement.Trading in the Shares of the Company has been suspended on the Stock Exchange since 9:00 a.m. on 18 July, 2025, pending the release of this Announcement. The Company has applied to the Stock Exchange for the resumption of trading of Shares with effect from 9 a.m. on August 13, 2025.J.P. Morgan acted as the exclusive financial advisor to the Offeror.Kangji Medical Holdings LimitedKangji Medical is a medical device group founded in 2004 with headquarters at Hangzhou, Zhejiang Province, China. It was listed at the mainboard of the Stock Exchange of Hong Kong in June 2020 (Stock Code: 9997.HK). The Company specializes in the design, development, manufacture and sale of minimally invasive surgery instruments and accessories (“MISIA”). It strives for the mission of “providing physicians with high-quality products and services, and dedicating to improve people’s health”. The Company offers a comprehensive product portfolio to provide physicians and hospitals one-stop and tailored surgical solutions primarily for four major surgical specialties, including obstetrics and gynecology, general surgery, urology, and thoracic surgery. It is also committed to developing an internationally recognized minimally invasive surgery instruments and accessories platform with global coverage.About Knight Bidco LimitedEach of the Offeror, MidCo and TopCo is a newly incorporated company in the Cayman Islands with limited liability and an investment holding company set up solely for the purposes of implementing the Proposal. As at the date of the announcement, the Offeror is wholly owned by MidCo, which in turn is wholly owned by TopCo. As at the date of this announcement, TopCo is held by the Consortium Members, as to approximately 25.53% by Fortune Spring ZM, approximately 14.47% by Fortune Spring YG, approximately 24.38% by TPG Asia VII, approximately 5.01% by Keyhole, approximately 5.69% by Knight Success, approximately 4.56% by NewQuest V and approximately 20.36% by Al-Rayyan Holding. As at the date of this announcement, save as disclosed in the section headed “Shareholding Structure of the Company” in the Joint Announcement, none of TPG Asia VII, Keyhole, Knight Success, NewQuest V and Al-Rayyan Holding is a Shareholder.Kangji Medical is controlled by Mr. Zhong and his spouse Ms. Shentu who together hold 52.98% of the shares in Kangji Medical. Following the privatisation of Kangji Medical, Mr. Zhong and Ms. Shentu will remain the largest shareholders in the ultimate parent company of the Offeror, holding 40.00% of the shares in TopCo via Fortune Spring ZM and Fortune Spring YG. Further details are available in the Joint Announcement.Each of the Founder Entities is a business company incorporated in the British Virgin Islands.Knight Success is a newly incorporated company in Singapore with limited liability and an investment holding company. Keyhole is an exempted company incorporated in the Cayman Islands with limited liability and an investment holding company. TPG Asia VII is a company incorporated in Singapore with limited liability. Each of Knight Success and Keyhole is either wholly owned or controlled by TPG Asia VII, which is in turn controlled by TPG Asia GenPar VII Advisors, Inc. and ultimately controlled by TPG Inc., a publicly traded Delaware corporation (NASDAQ).TPG is a leading global alternative asset management firm founded in 1992 with more than US$269 billion of assets under management as of 30 June 2025. For many years, TPG has been investing in transformation, growth, and innovation and aims to build dynamic products and strategies for its investors while also instituting discipline and operational excellence across its investment strategies and performance of its portfolios.NewQuest V is a company incorporated in Singapore with limited liability and an investment holding company. NewQuest V is wholly owned by NewQuest Asia Fund V, L.P., which is in turn controlled by NewQuest Asia Fund V GP Ltd. and ultimately controlled by TPG Inc., a publicly traded Delaware corporation (NASDAQ).Established in 2011, NewQuest is one of Asia’s leading secondary private equity platforms with the most experienced secondary team in Asia across five offices. Since its founding, NewQuest has focused on working with GPs to create bespoke, tailored solutions to meet liquidity and other strategic needs of private asset owners and their stakeholders. Starting from a strategic partnership forged in 2018, NewQuest became wholly owned by TPG in January 2022.Al-Rayyan Holding is a limited liability company established in 2012 under the regulations of the Qatar Financial Centre Authority in the State of Qatar, and is a 100%-owned indirect subsidiary of QIA, the sovereign wealth fund of the State of Qatar. QIA was founded in 2005 to invest and manage the state reserve funds. QIA is among the largest and most active sovereign wealth funds globally. QIA invests across a wide range of asset classes and regions as well as in partnership with leading institutions around the world to build a global and diversified investment portfolio with a long-term outlook. As at the date of this announcement, Al-Rayyan Holding and its concert parties (other than those who are, or deemed to be, acting in concert with Al-Rayyan Holding solely in connection with the Consortium) are not interested in any Shares.For enquiries, please contact:Kangji Medical Holdings LimitedOfferorMedia contact: Wonderful Sky Financial Group LimitedAngie Li & Jason LaiTel: +852 6150 8598 / +852 9798 0715Email: po@wsfg.hkMedia contact: Brunswick GroupKatelin Stevenson & Tong Li+852 9875 3351 / +86 134 8872 6729TeamKnight@brunswickgroup.com[1] Based on HK$9.25 Cancellation Price per share, 1,207,994,000 shares outstanding, and USD/HKD of 7.85All capitalized terms which are used in this press release but not otherwise defined herein shall have the meanings ascribed to them in the Joint Announcement dated 12 August, 2025. This press release should be read in conjunction with the Joint Announcement, a copy of which is available on https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0812/2025081201338.pdf. Copyright 2025 ACN Newswire via SeaPRwire.com.

香港，2025年8月13日 - (亚太商讯 via SeaPRwire.com) - 备受全球科技界关注的世界人形机器人运动会将于8月14日在北京国家速滑馆正式拉开帷幕，这场持续至8月17日的科技盛宴，将成为展现全球人形机器人技术最高水平的重要窗口。作为全球首个以人形机器人为核心参赛主体的大型综合性赛事，本次运动会设置了极具看点的多元竞赛项目。来自世界各地的超百支顶尖机器人战队，将在跑步、足球、街舞、武术、工厂搬运、酒店服务等项目上进行比拼，全面展示人形机器人在不同领域的应用潜力。这背后不仅是技术的较量，更是对机器人适应复杂环境、完成精细任务能力的全方位检验，每一个项目的背后都凝聚着人工智能、机械工程等多学科的技术突破。一、首程控股多维度深度参与本届运动会中，首程控股扮演了资本推动者、场景验证者与生态运营者的三重角色。依托管理的北京机器人产业发展投资基金及多支产业基金，首程已系统投资布局数十家高成长机器人企业，覆盖从核心零部件到整机集成、从底层算法到场景应用的全产业链。此次亮相的被投企业包括：宇树科技（Unitree Robotics）、银河通用（Galbot）、星海图（Galaxea-AI）、松延动力（Noetix Robotics）、加速进化（Booster Robotics）、自变量机器人（X Square Robot）等，分别在足球、田径、格斗、舞蹈、场景赛等核心项目中担纲主力。二、首程机器人科技体验店打造沉浸式产业橱窗运动会期间，位于国家速滑馆内的首程机器人科技体验店同步开放，集中展示50余家企业近200款产品，涵盖智慧家居、教育、智能穿戴、娱乐休闲等多个场景。观众不仅可以近距离体验人形机器人、智能家电、AI娱乐设备等前沿产品，还可现场购买，实现"发布-测试-销售-服务"的消费闭环。这一举措与首程2025年启动的全球"机器人综合体验店"招募计划一脉相承，将为后续在融石广场等地开设的长期体验店积累场景与运营经验。首程控股董事会主席赵天旸表示，机器人市场规模未来将超越汽车行业，中国必将诞生百亿美元市值的机器人企业。而通过运动会这一"产业橱窗"，首程不仅展示被投企业技术实力，更在真实环境中验证其商业化潜力，加速技术从"实验室走向市场"的进程。三、租赁公司保障赛事落地 为保障赛事前期训练与正式比赛，北京机器人租赁公司集中交付了100台赛事指定设备，包括82台加速进化足球赛本体、10台松延动力田径机器人和8台银河通用场景赛机器人。设备已全部进驻国家速滑馆，重点服务足球赛、田径赛及场景赛的训练需求，并由租赁公司与厂商技术团队联合驻场提供全流程技术支持，实现"即交付、即服务"的产业响应。观赛互动福利为感谢市场长期以来的支持，首程控股将通过抽签选出88位幸运观众亲临现场，共同见证这场全球顶尖科技的竞技舞台。报名注册截止日期：北京时间2025年8月14日上午9:00抽签时间：2025年8月14日下午3点前公布，受邀者将收到邮件或短信通知参与方式1.通过链接填写报名信息：https://www.wjx.cn/vm/mfW64yI.aspx#2.关注"首程控股"官方微信公众号，后台留言「机器人运动会」，根据弹出链接填写报名信息。 Copyright 2025 亚太商讯 via SeaPRwire.com.

康基医疗控股有限公司与Knight Bidco Limited今日联合宣布，拟通过协议安排（"建议交易"）对公司进行私有化。康基医疗控股有限公司私有化要约：每股9.25港元的注销价较股份于截至未受干扰日期（即2025年6月30日）之收盘价溢价约21.7%，较股份于截至未受干扰日期（包括该日）止360个交易日在联交所所报的平均收盘价溢价约47.3%，且超过了2022年以来于联交所录得之最高收盘价。本次私有化拟以协议安排方式实施，要约人及其一致行动人士合共持有公司74.75%之股份；已获得一家机构股东作出的不可撤销承诺，将投票支持该私有化方案。该方案为股东提供明确机会，使其能够于康基医疗控股有限公司之股份持续面临交易价格压力及流动性受限之际，变现其于公司之权益。香港，2025年8月13日 - (亚太商讯 via SeaPRwire.com) - 2025年8月12日，康基医疗控股有限公司（"康基医疗"或"公司"，股份代号：9997.HK）与KNIGHT BIDCO LIMITED"要约人"今日联合宣布，双方拟以协议安排的方式对公司进行私有化，以期公司能够专注于长期战略决策，包括研发长期投入及运营升级。待该方案完成后，公司将成为要约人的全资附属公司，而公司股份于联交所的上市地位将被撤销。要约人由以下成员组成的财团全资持有：钟先生与申屠女士（创始人）、TPG实体、NewQuest V基金及Al-Rayyan Holding。交易理据鉴于股票的交易价格持续承压且流动性长期不足，公司从股票市场筹集资金的能力受到严重限制。除此之外，本公司为维持上市地位须承担行政、合规及其他与上市相关之成本及开支，故维持上市地位之裨益有限。由于国内市场竞争加剧及持续之监管不确定性，为实现可持续增长，公司的长期策略需进行重大投资，此举可能对短期财务表现造成压力。预计需将额外资源分配至以下领域：销售与市场推广、研发及商业化投资，以及中国境外之市场扩张。鉴于维持上市地位的裨益有限，且涉及相关上市成本，康基医疗继续维持上市地位之必要性已显著降低。此外，该方案的实施将缓解公司短期财务表现所受压力，从而更专注于战略目标的推进。公司预期需要配置更多资源，以保障其未来可持续发展。此外，该方案为少数股东提供具吸引力的机会，使其能在市场波动、行业及宏观不确定性，以及股份流动性有限之情况下，实现可观回报。KNIGHT BIDCO LIMITED提出的私有化方案为康基医疗及其股东提供了及时有效的解决方案，提议将康基医疗私有化的方案将：(a) 降低康基医疗的行政、合规及其他上市相关成本；(b) 缓解康基医疗面临的短期业绩指标压力，使康基医疗能够专注于长远战略决策（例如可能导致短期亏损的长期研发投入及运营升级）；以及(c) 为现有股东提供明确保障，使其能以显著高于未受干扰股价的溢价，实现于康基医疗的权益变现。综上所述，要约方认为私有化交易能为全体股东提供即时且最具吸引力价值的战略选择，同时可规避不确定市场环境带来的风险。交易方案概述本次私有化方案设定的股份注销价格为每股9.25港元，按股权价值计算对公司估值约为14亿美元[1]。要约方已明确表示，注销价格为最终定价且后续不会上调。该注销价格体现以下考量：较股份于未受干扰日期（即2025年6月30日）在联交所所报收盘价溢价约21.7%。较股份于截至未受干扰日期（包括该日）止360个交易日在联交所所报的平均收盘价溢价约47.3%。以及截至未受干扰日期（包括该日）止于联交所所报之股份价格的过去52周最低收盘价（5.01港币）溢价约84.6%。此外，在较长的过往期间内，注销价格超过了股份自2022年以来的最高收盘价（8.66港币）。本次注销价格的确定已综合考量下列因素（包括但不限于），股份于联交所的近期及历史交易价格，公司公开披露的财务资讯，及参照近年来香港市场类似私有化交易案例。该方案的实施受限于所有先决条件于2026年1月31日（先决条件最后截止日期）或之前达成，并在2026年4月30日（最后截止日）之前满足条件。公司将委任独立财务顾问（"IFA"）向为方案目的而设立的独立董事委员会（"独立董事委员会"）提供意见，以便就方案向股东作出推荐建议。方案的详情，包括独立董事委员会的最终推荐意见及独立财务顾问的意见函，将载入计划文件，并预期在切实可行的情况下尽快寄发给股东。协议安排会议协议安排会议的具体细节将载于计划文件，该文件预计将于适当时候寄发予股东。本次交易尚需满足《联合公告》所列的多项先决条件及条件，包括但不限于监管批准、股东批准及其他法定合规要求。不可撤销承诺本公司已获得一名机构股东作出的不可撤销承诺，将就该项提案投赞成票。详情请参阅《联合公告》。康基医疗已于2025年7月18日上午9时正起于联交所暂停买卖，以待刊发本公告。公司已向联交所申请股份自2025年8月13日上午9点起恢复买卖。摩根大通担任要约方独家财务顾问。关于康基医疗控股有限公司康基医疗控股有限公司创立于2004年，总部位于中国浙江省杭州市，于2020年6月在香港联合交易所主板上市，股票代码9997.HK。公司专注于设计、开发、生产和销售微创外科手术器械及配套耗材（"MISIA"），秉持着"为医生提供优质产品和服务，致力于人类健康事业"为使命，通过丰富的产品组合为妇产科、普外科、泌尿外科和胸外科等临床科室的微创外科手术提供一站式解决方案，并致力于发展为一个立足中国，辐射全球的国际化微创外科手术器械及配套耗材平台。关于Knight Bidco Limited要约人、MidCo 及TopCo均为于开曼群岛新注册成立的有限公司及仅为实施该建议而成立的投资控股公司。于公告日期，要约人由MidCo全资拥有，而MidCo由TopCo全资拥有。于本公告日期，TopCo由财团成员持有，其中Fortune Spring ZM、Fortune Spring YG、TPG Asia VII、Keyhole、Knight Success、NewQuest V及Al-Rayyan Holding分别持有约25.53%、约14.47%、约24.38%、约5.01%、约5.69%、约4.56%及约20.36%。于本公告日期，除《联合公告》中"公司的股权架构"一节所披露外，TPG Asia VII、Keyhole、Knight Success、NewQuest V及Al-Rayyan Holding均非股东。康基医疗现由钟鸣先生及其配偶申屠女士共同控制，二人合计持有康基医疗52.98%股份。待私有化完成后，钟氏夫妇将通过Fortune Spring ZM与Fortune Spring YG继续持有要约方最终控股公司（TopCo）40.00%股权，并保持第一大股东地位。更多细节详见《联合公告》。各创始人实体均为在英属维尔京群岛注册成立的商业公司。Knight Success为一家于新加坡新注册成立的有限公司且为一家投资公司。Keyhole为一家于开曼群岛注册成立之获豁免有限公司及投资控股公司。TPG Asia VII为一家于新加坡注册成立的有限公司。Knight Success及Keyhole均由TPG Asia VII全资拥有或控制，而后者由TPG Asia GenPar VII Advisors, Inc.控制，并最终由纳斯达克上市的特拉华州公司TPG Inc.控制。TPG是一家全球领先的另类资产管理公司，成立于1992年，截至2025年6月30日年管理的资产超过2,690亿美元。多年来，TPG一直致力于投资变革、增长与创新，旨在为投资者构建多元化的产品与策略，同时借由贯彻纪律及卓越的营运管理，提升投资策略与投资组合的整体表现。NewQuest V为一家于新加坡注册成立的有限公司及投资控股公司。NewQuest V由NewQuest Asia Fund V, L.P.全资拥有，而后者由NewQuest Asia Fund V GP Ltd.控制，并最终由纳斯达克上市的特拉华州公司TPG Inc.控制。NewQuest成立于2011年，是亚洲领先的二级私募股权平台之一，拥有亚洲最有经验的二级团队，分布于五个办事处。自成立以来，NewQuest一直专注于与普通合伙人合作，创建定制的解决方案，以满足私募资产持有人及其利益相关者的流动性和其他战略需求。从2018年建立的战略合作伙伴关系开始，NewQuest2022年1月成为TPG的全资附属公司。Al-Rayyan Holding为一家根据卡塔尔金融中心管理局的规定于2012年在卡塔尔成立的有限责任公司，且为卡塔尔主权财富基金卡塔尔投资局全资拥有的间接附属公司。成立于2005年的卡塔尔投资局旨在投资和管理国家储备基金。卡塔尔投资局为全球最大、最活跃的主权财富基金之一。卡塔尔投资局投资于广泛的资产类别及地区，并与世界各地的领先机构合作，建立具有长期前景的全球化及多元化投资组合。于本公告日期，Al-Rayyan Holding及其一致行方（与Al-Rayyan Holding 单独或被视为与该财团一致行事的各方除外）均不持有任何股份。如有垂询，敬请联系：康基医疗控股有限公司要约人传媒联络：皓天财经集团有限公司Angie Li & Jason Lai电话：(+852) 6150 8598 / (+852) 9798 0715电邮：po@wsfg.hk传媒联络: 博然思维Kay Lau电话：+852 6021 7009Tong Li电话：+86 134 8872 6729电邮：TeamKnight@brunswickgroup.com[1] 以每股9.25港币的注销价格、1,207,994,000股流通股，以及7.85的美元兑港币汇率计算免责声明：本新闻稿中使用的所有未另行定义的大写术语，其含义均以2025年8月12日发布的《联合公告》中的释义为准。本新闻稿须与《联合公告》全文一并阅读，公告副本可在以下链接查阅。https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0812/2025081201339_c.pdf Copyright 2025 亚太商讯 via SeaPRwire.com.

HONG KONG, Aug 8, 2025 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK) recently announced the Taiwan Food and Drug Administration (TFDA) has approved the supplementary application for NEFECON(R). NEFECON(R) is indicated to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression, irrespective of proteinuria levels.With this label update, the previous requirement in accelerated approval stage to submit full confirmatory trial analysis to demonstrate clinical benefit has been formally removed. Additionally, data demonstrating NEFECON(R)’s efficacy in delaying kidney function decline has been included in the approved product label. IgAN is highly prevalent among Asian populations, with a 56% higher risk of progression to end-stage renal disease compared to other groups and often progresses more rapidly.Taiwan region became the last region across all Everest’s territories to grant full approval for NEFECON(R), together with Mainland China, Singapore, Macao SAR, Hong Kong SAR and South Korea. This further demonstrates NEFECON(R)’s foundational first-line cornerstone treatment for IgAN patients."NEFECON(R) has received full approval in Taiwan, further validating its outstanding clinical value and offering physicians a more solid clinical foundation for treatment decisions.” Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines, said. “As the first and only fully approved etiological treatment for IgAN, NEFECON(R) has now achieved full approval across Asia. This milestone will benefit a broader patient population by enabling more individuals with IgAN to access this etiological treatment earlier, helping to slow disease progression and improve quality of life. We will continue to expand the accessibility and affordability of NEFECON(R) across Asia, aiming to benefit more IgAN patients and improve their quality of life."The approval is based on the global Phase 3 NefIgArd clinical trial, which showed that compared to placebo, it not only brought about a durable reduction in proteinuria and reduced the frequency of microscopic hematuria but also demonstrated clinically relevant and statistically significant treatment benefits in estimated glomerular filtration rate (eGFR), reducing the decline in kidney function by 50% over a period of 2 years, comprising 9 months of treatment and 15 months of observation, and potentially delaying the progression to dialysis or kidney transplantation by 12.8 years.Additionally, the complete 2-year data of the NefIgArd study further analyzed the potential differences in the response to NEFECON(R) treatment between Asians (n=83) and Caucasians (n=275). The results showed that compared to placebo, treatment with NEFECON(R) for 9 months in both Asians and Caucasians can significantly delay the decline of eGFR, protect kidney function, and bring about a sustained reduction in proteinuria and reduce the risk of microscopic hematuria.NEFECON(R) has been recommended by several authoritative treatment guidelines, including the “KDIGO 2024 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV) (Public Review Draft)”, and the "Clinical Practice Guideline for IgA Nephropathy and IgA Vasculitis in Chinese Adults (For Public Review)". NEFECON(R) was included in China’s National Reimbursement Drug List (NRDL) in November 2024, and the supplemental application for the production expansion of NEFECON(R) has been officially approved by NMPA in August 2025.NEFECON(R) is currently the world’s first IgAN treatment to have received full approval from the National Medical Products Administration (NMPA) in China, the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Medicines and Healthcare products Regulatory Agency（MHRA）in the United Kingdom , as well as in other Asian territories where Everest Medicines holds the rights, including Hong Kong SAR, Macao SAR, Taiwan region (China), Singapore, and South Korea. Copyright 2025 ACN Newswire via SeaPRwire.com.